Their clinical utility could mirror precision strategies already in use, such as trastuzumab for HER2-positive uterine serous carcinoma [19], [20], demonstrating how biomarker-informed ML tools can personalize care and improve outcomes. This evidence concerns the gene ERBB2 and endometrial serous adenocarcinoma.